Nachrichten, Ressourcen, Aktuelles
Eine wissenschaftliche Plattform, die Sie über unsere neuesten Forschungsergebnisse und Unternehmensnachrichten auf dem Laufenden hält.
InnoSer und OrganoTherapeutics bieten Organoide des Mittelhirns an
InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...
Strategische Partnerschaft zwischen InnoSer und TheraIndx
InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...
InnoSer erhält neue Zellkulturanlagen
InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...
Eurostars-Förderung für MINDMAP
53 million people were affected by Alzheimer’s Disease (AD) in 2013. This was a steep rise from 26.6 million in 2005, and the predictions for 2050 rise further to 106 million cases. Despite the growing demand for AD medicines not only to stabilize but also to treat...
Ein Sprung in die Zukunft: Entwicklung einer PDXO-Plattform für das Wirkstoffscreening
InnoSer NV, a young and innovative Belgium based Contract Research Organization (CRO) has received an over € 1.6 million grant from the Flemish VLAIO. This development grant is awarded to set up a PDXO screening platform in partnership with Vrije...
info@innoserlaboratories.com